Epizyme, Inc
EPZM
EPZM was delisted on the 11th of August, 2022.
75 hedge funds and large institutions have $494M invested in Epizyme, Inc in 2014 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 32 increasing their positions, 16 reducing their positions, and 6 closing their positions.
250% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 6
100% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 16
51% more capital invested
Capital invested by funds: $326M → $494M (+$168M)
25% more funds holding
Funds holding: 60 → 75 (+15)
7% more call options, than puts
Call options by funds: $876K | Put options by funds: $815K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$53.1M |
| 2 |
Primecap Management
Pasadena,
California
|
+$28.6M |
| 3 |
JP Morgan Chase
New York
|
+$18M |
| 4 |
Citigroup
New York
|
+$13.7M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
-$14.1M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$4.84M |
| 3 |
RFC
Russell Frank Company
Seattle,
Washington
|
-$2.77M |
| 4 |
BC
Broadfin Capital
New York
|
-$2.08M |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$1.22M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ARTA
76
A.R.T. Advisors
New York
| – | -$1.22M | -58,626 | Closed |
|
77
Jane Street
New York
| – | -$392K | -18,824 | Closed |
|
|
SO
78
STRS Ohio
Columbus,
Ohio
| – | -$294K | -9,700 | Closed |
|
79
Bank of America
Charlotte,
North Carolina
| – | -$135K | -4,453 | -100% |
|
80
Wells Fargo
San Francisco,
California
| – | -$4K | -200 | Closed |
|
81
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$121 | +4 | +22% |
|
EPZM Hedge Fund Activity: Q1 2014 in Review
75 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q1 2014, worth a combined $494M — up 51% from $326M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new EPZM positions and 6 closed out — a net gain of 15 holders — while 32 added to existing stakes and 16 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $53.1M. The largest seller was MPM Asset Management, cutting an estimated $14.1M.
- 75 institutional investors held Epizyme, Inc (EPZM) as of Q1 2014, up from 60 in Q4 2013.
- Funds reported $494M of Epizyme, Inc stock for Q1 2014, up 51% quarter-over-quarter.
- 21 funds opened new Epizyme, Inc positions in Q1 2014 and 6 closed out, a net change of +15 holders.
- The largest Epizyme, Inc buyer in Q1 2014 was Fidelity Investments, an estimated $53.1M added.
- The largest Epizyme, Inc seller in Q1 2014 was MPM Asset Management, an estimated $14.1M sold.
Based on aggregated 13F filings for Q1 2014.